Sclerotherapy in the treatment of pyogenic granuloma
Abstract
Backgound Pyogenic granuloma would be defined as the benign growth composed of clusters of hyperplastic capillaries divided into lobules by fibromyxoid stroma. The limited therapeutic effect and the high recurrence rates associated with traditional treatment modalities, in addition to large size and occurrence of some lesions in surgically difficult areas necessitate the seek for an alternative therapeutic approach. Sclerotherapy is not routinely reported as an option for treating pyogenic granuloma.  Objective To assess the tolerability and efficiency of sclerotherapy (polidocanol solution 3%) in pyogenic granuloma treatment.  Methods An open-labeled, interventional therapeutic trial conducted from December 2020 to September 2021. Patients who were diagnosed clinically with PG were enrolled in the study and treated by intralesional injections of polidocanol solution 3%.  Results There was significant reduction in the mean of lesion sizes during the second visit when put head-to-head with the first visit, the reduction was also present in the third visit when compared to the first two (P value <0.05). Moreover, nearly 62.5% of patients showed complete resolution during the second visit and the remaining 37.5% resolved completely during the third visit. A significant moderate negative correlation was detected between duration of the lesions and resolution. Other factors, like age, gender, site and sizes of the lesions, didn’t have significant impact on response to treatment.  Conclusion Sclerotherapy with polidocanol solution 3% is a safe and effective treatment for pyogenic granuloma. ÂReferences
Giblin AV, Clover AJP, Athanassopoulos A, Budny PG. Pyogenic granuloma – the quest for optimum treatment: Audit of treatment of 408 cases. J Plast Reconstr Aesthet Surg. 2007;60(9):1030–5.
Song MG, Kim HJ, Lee ES. Intravenous pyogenic granuloma: Intravenous pyogenic granuloma. Int J Dermatol. 2001;40(1):57–9.
Harris MN, Desai R, Chuang TY, Hood AF, Mirowski GW. Lobular capillary hemangiomas: An epidemiologic report, with emphasis on cutaneous lesions. J Am Acad Dermatol. 2000;42(6):1012–6.
Wollina U, Langner D, França K, Gianfaldoni S, Lotti T, Tchernev G. Pyogenic Granuloma – A Common Benign Vascular Tumor with Variable Clinical Presentation: New Findings and Treatment Options. Open Access Maced J Med Sci. 2017;5(4):423–6.
Henning B, Stieger P, Kamarachev J, Dummer R, Goldinger SM. Pyogenic granuloma in patients treated with selective BRAF inhibitors: another manifestation of paradoxical pathway activation. Melanoma Res. 2016;26(3):304–7.
Robert C, Sibaud V, Mateus C, Verschoore M, Charles C, Lanoy E, et al. Nail toxicities induced by systemic anticancer treatments. Lancet Oncol. 2015;16(4):e181-9.
Cardoso JA, Spanemberg JC, Cherubini K, DE Figueiredo MAZ, Salum FG. Oral granuloma gravidarum: a retrospective study of 41 cases in Southern Brazil. J Appl Oral Sci. 2013;21(3):215–8.
Dastgheib L, Maghami Z, Aslani FS. Infantile multiple large pyogenic granuloma on burned skin. Case report and review of literature. An Bras Dermatol. 2016;91(2):212–4.
Piraccini BM, Bellavista S, Misciali C, Tosti A, Berker DD, Richert B. Periungual and subungual pyogenic granuloma. Br J Dermatol. 2010;163(5):941–53.
Zaballos P, Carulla M, Ozdemir F, Zalaudek I, Bañuls J, Llambrich Ã, et al. Dermoscopy of pyogenic granuloma: a morphological study: Dermoscopy of pyogenic granuloma. Br J Dermatol. 2010;163(6):1229–37.
Bolognia JL, editor. Dermatology: ExpertConsult. 3rd edition ff. Edinburgh: Elsevier; 2012:2026-27.
Koo MG, Lee SH, Han SE. Pyogenic Granuloma: A Retrospective Analysis of Cases Treated Over a 10-Year. Arch Craniofacial Surg. 2017;18(1):16–20.
Mirshams M, Daneshpazhooh M, Mirshekari A, Taheri A, Mansoori P, Hekmat S. Cryotherapy in the treatment of pyogenic granuloma. J Eur Acad Dermatol Venereol. 2006;20(7):788–90.
Fekrazad R, Nokhbatolfoghahaei H, Khoei F, Kalhori KA. Pyogenic Granuloma: Surgical Treatment with Er:YAG Laser. J Lasers Med Sci. 2014;5(4):199–205.
Dany M. Beta-Blockers for Pyogenic Granuloma: A Systematic Review of Case Reports, Case Series, and Clinical Trials. J Drugs Dermatol. 2019;18(10):1006-10.
Sharquie K, Noaimi A, Radhi S. Burn Hemangioma (BH) (Scalded Pyogenic Granuloma) versus Infantile Hemangioma: Report of Six Cases of BH and Its Effective Therapy with Oral Propranolol. J Cosmet Dermatol Sci Appl. 2017;07:229–44.
Khunger N, Sacchidanand S. Standard guidelines for care: Sclerotherapy in dermatology. Indian J Dermatol Venereol Leprol. 2011;77(2):222–31.
Samatha Y, Reddy TH, Jyothirrmai null, Ravikiran A, Sankar AJS. Management of oral pyogenic granuloma with sodium tetra decyl sulphate. A case series. N Y State Dent J. 2013;79(4):55–7.
Rahman H, Hadiuzzaman D. Pyogenic granuloma successfully cured by sclerotherapy: A case report. J Pak Assoc Dermatol. 2014;24(4):361–4.
Zhao Z, Liu C, Wu H, Zhao H, Zheng J. Sclerotherapy with Polidocanol Foam is a Promising Perspective Treatment for Pyogenic Granuloma: A Retrospective Analysis in 52 Cases. Clin Surg. 2019;4(1):2680.
Eckmann DM. Polidocanol for Endovenous Microfoam Sclerosant Therapy. Expert Opin Investig Drugs. 2009;18(12):1919–27.
Bansal N, Belgaumkar VA,Chavan RB, Doshi BR. Successful Treatment of Pyogenic Granuloma with Sclerotherapy. Indian J Drugs Dermatol. 2019;5(1):30-3.
Khaitan T, Sinha R, Sarkar S, Kabiraj A, Ramani D, Sharma M. Conservative approach in the management of oral pyogenic granuloma by sclerotherapy. J Indian Acad Oral Med Radiol. 2018;30(1):46–51.
Khurana A, Mathachan SR. Polidocanol Sclerotherapy in Pyogenic Granulomas. Dermatol Surg Off Publ Am Soc Dermatol Surg Al. 2021.
Shah JS, Ranghani AF. Sclerotherapy in pyogenic granuloma and mucocele. J Indian Acad Oral Med Radiol. 2018;30(3):230–4.
Carvalho RA, Neto V. Letter: Polidocanol Sclerotherapy for the Treatment of Pyogenic Granuloma. Dermatol Surg. 2010;36:1068–70.
Sacchidanand S, Purohit V. Sclerotherapy for the Treatment of Pyogenic Granuloma. Indian J Dermatol. 2013;58(1):77–8.
